Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: Eur J Nucl Med Mol Imaging

Search In Journal Title:

Abbravation: European Journal of Nuclear Medicine and Molecular Imaging

Search In Journal Abbravation:

Publisher

Springer-Verlag

Search In Publisher:

DOI

10.1007/bfb0059837

Search In DOI:

ISSN

1619-7089

Search In ISSN:
Search In Title Of Papers:

Molecular imaging of angiogenesis with SPECT

Authors: Ingrid Dijkgraaf Otto C Boerman
Publish Date: 2010/07/09
Volume: 37, Issue: 1, Pages: 104-113
PDF Link

Abstract

Singlephoton emission computed tomography SPECT and position emission tomography PET are the two main imaging modalities in nuclear medicine SPECT imaging is more widely available than PET imaging and the radionuclides used for SPECT are easier to prepare and usually have a longer halflife than those used for PET In addition SPECT is a less expensive technique than PET Commonly used gamma emitters are 99mTc Emax 141 keV T 1/2 602 h 123I Emax 529 keV T 1/2 130 h and 111In Emax 245 keV T 1/2 672 h Compared to clinical SPECT PET has a higher spatial resolution and the possibility to more accurately estimate the in vivo concentration of a tracer In preclinical imaging the situation is quite different The resolution of microSPECT cameras 05 mm is higher than that of microPET cameras 15 mm In this report studies on new radiolabelled tracers for SPECT imaging of angiogenesis in tumours are reviewedAngiogenesis the formation of new blood vessels from preexisting vasculature is one of the key requirements if solid tumours are to grow beyond 2–3 mm3 since diffusion is no longer sufficient to supply the tissue with oxygen and nutrients 1 Tumourinduced angiogenesis is a complex multistep process that follows a characteristic cascade of events mediated and controlled by growth factors cellular receptors and adhesion molecules 2 3 4 In this process five phases can be distinguished 1 endothelial cell activation 2 basement membrane degradation 3 endothelial cell migration 4 vessel formation and 5 angiogenic remodelling 5The activation of preexisting quiescent vessels can be triggered by hypoxia Hypoxia induces the expression of hypoxiainducible factor HIF which binds to the hypoxic response element As a result the expression of hypoxiainducible genes such as vascular endothelial growth factor VEGF carbonic anhydrase IX CAIX plateletderived growth factor PDGF and transforming growth factorα TGFα is induced 6Activated endothelial cells express the dimeric transmembrane integrin αvβ3 which interacts with extracellular matrix proteins vitronectin tenascin fibronectin ao and regulates migration of the endothelial cell through the extracellular matrix during vessel formation 7 8 The activated endothelial cells synthesize proteolytic enzymes such as matrix metalloproteinases MMPs used to degrade the basement membrane and the extracellular matrix 9 Initially endothelial cells assemble as solid cords Subsequently the inner layer of endothelial cells undergoes apoptosis leading to the formation of the vessel lumen Finally this primary immature vasculature undergoes extensive remodelling during which the vessels are stabilized by pericytes and smooth muscle cells This step is often incomplete in tumours resulting in the characteristic increased permeability of tumour vesselsBased on a balance between proangiogenic and antiangiogenic factors a tumour can stay dormant for a very long time period until the socalled angiogenic switch occurs In most tissues tumours can only grow to a lifethreatening size if the tumour is able to trigger angiogenesis In tissues with high vessel densities eg liver brain ao tumours may also progress via angiogenesisindependent cooption of the preexistent vasculature 10In summary tumourinduced angiogenesis is a multistep process and a key feature of a tumour lesion that has major impact on the biological behaviour of the lesion Inhibition of angiogenesis is a new cancer treatment strategy that is now being widely investigated clinically Researchers have begun to search for objective measures that indicate pharmacological responses to antiangiogenic drugs Therefore there is great interest in techniques to visualize angiogenesis in growing tumours noninvasively During the past decade several markers of angiogenesis have been identified and specific tracers targeting these markers have been developedVEGF is a key regulator of angiogenesis during embryogenesis skeletal growth and reproductive functions The expression of VEGF is upregulated by environmental stress caused by hypoxia anaemia myocardial ischaemia and tumour progression to initiate neovascularization 11 Via alternative mRNA splicing the human VEGFA gene gives rise to four isoforms having 121 165 189 and 206 amino acids VEGF121 VEGF165 VEGF189 and VEGF206 respectively 12 13 Less frequent splice variants have been identified more recently including VEGF145 14 VEGF183 15 VEGF162 16 and VEGF165b 17 The VEGF isoforms differ not only in their molecular mass but also in their solubility and receptorbinding characteristicsInitially VEGF receptors were identified on the cell surface of vascular endothelial cells in vitro 18 19 and in vivo 20 21 Subsequently it was demonstrated that receptors for VEGF also are expressed on bone marrowderived cells such as monocytes 22 VEGFA binds two related receptor tyrosine kinases RTKs VEGFR1 and VEGFR2 Both receptors consist of seven Iglike domains in the extracellular domain a single transmembrane region and a consensus tyrosine kinase sequence that is interrupted by a kinase insert domain 23 24 25 VEGFR1 binds VEGF with a higher affinity compared to VEGFR2 Kd 25 vs 75–250 pM 26 27 28 VEGFR1 is considered to be a decoy receptor and VEGFA only signals through VEGFR2 29


Keywords:

References


.
Search In Abstract Of Papers:
Other Papers In This Journal:

  1. Protocol for measuring myocardial blood flow by PET/CT in cats
  2. Coronary risk factors and myocardial blood flow in patients evaluated for coronary artery disease: a quantitative [ 15 O]H 2 O PET/CT study
  3. Comparison of [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotate and [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotide: which peptide is preferable for PRRT?
  4. Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer’s disease assessed with positron emission tomography
  5. Assessment of the diagnostic accuracy of 18 F-FDG PET/CT in prosthetic infective endocarditis and cardiac implantable electronic device infection: comparison of different interpretation criteria
  6. Left ventricular diastolic dyssynchrony assessed with phase analysis of gated myocardial perfusion SPECT: a comparison with tissue Doppler imaging
  7. Non-invasive estimation of hepatic glucose uptake from [ 18 F]FDG PET images using tissue-derived input functions
  8. Non-invasive estimation of hepatic glucose uptake from [ 18 F]FDG PET images using tissue-derived input functions
  9. Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging
  10. Differentiation of hepatocellular adenoma and focal nodular hyperplasia using 18 F-fluorocholine PET/CT
  11. Pharmacokinetics of [ 18 F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer’s disease
  12. Can 68 GA-PSMA or radiolabeled choline PET/CT guide salvage lymph node dissection in recurrent prostate cancer?
  13. Brain reserve capacity in frontotemporal dementia: a voxel-based 18 F-FDG PET study
  14. In-vivo comparison of the acute retention of stem cell derivatives and fibroblasts after intramyocardial transplantation in the mouse model
  15. Characterization of age/sex and the regional distribution of mGluR5 availability in the healthy human brain measured by high-resolution [ 11 C]ABP688 PET
  16. Assessment of infarct size by positron emission tomography and [ 18 F]2-fluoro-2-deoxy- D -glucose: a new absolute threshold technique
  17. 99m TcO(BAT-NI), a novel nitroimidazole tracer: in vivo uptake studies in ischaemic myocardium
  18. How should we analyse FDG PET studies for monitoring tumour response?
  19. Effects of nicorandil on cardiac sympathetic nerve activity after reperfusion therapy in patients with first anterior acute myocardial infarction
  20. Positron emission tomography in the management of lymphomas: a summary
  21. Pre- and postsynaptic dopamine SPECT in the early phase of idiopathic parkinsonism: a population-based study
  22. Impact of 131 I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma
  23. SPECT imaging of D 2 dopamine receptors and endogenous dopamine release in mice
  24. Molecular imaging of vascular cell adhesion molecule-1 expression in experimental atherosclerotic plaques with radiolabelled B2702-p
  25. A comparison of 99m Tc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping
  26. α v β 3 imaging can accurately distinguish between mature teratoma and necrosis in 18 F-FDG-negative residual masses after treatment of non-seminomatous testicular cancer: a preclinical study
  27. Comparison of the pharmacokinetics of 68 Ga-DOTATOC and [ 18 F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90 Y-DOTATOC therapy
  28. Integrated SPECT/CT for assessment of haemodynamically significant coronary artery lesions in patients with acute coronary syndrome
  29. Losartan renography for the detection of renal artery stenosis: comparison with captopril renography and evaluation of dose and timing
  30. Requirements regarding dose rate and exposure time for killing of tumour cells in beta particle radionuclide therapy
  31. Influence of blood glucose level, age and fasting period on non-pathological FDG uptake in heart and gut
  32. Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice
  33. Functional sex differences in human primary auditory cortex
  34. Rapid normalization of osseous FDG uptake following traumatic or surgical fractures
  35. Metabotropic glutamate receptor 5 – a promising target in drug development and neuroimaging
  36. Repeatability of hypoxia PET imaging using [ 18 F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial
  37. Assessment of inflammation in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia
  38. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer
  39. Erratum to: Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis
  40. Drug enhancement of myocardial tracer uptake during myocardial perfusion imaging
  41. Concomitant radio- and fluorescence-guided sentinel lymph node biopsy in squamous cell carcinoma of the oral cavity using ICG- 99m Tc-nanocolloid
  42. Occult lung infarction may induce false interpretation of 18 F-FDG PET in primary staging of pulmonary malignancies
  43. Aortic inflammation, as assessed by hybrid FDG-PET/CT imaging, is associated with enhanced aortic stiffness in addition to concurrent calcification
  44. Preoperative mapping of cortical language areas in adult brain tumour patients using PET and individual non-normalised SPM analyses
  45. Biodistribution and radiation dosimetry of 68 Ga-PSMA HBED CC—a PSMA specific probe for PET imaging of prostate cancer
  46. From the atomon of Democritus to the therapeutic nuclear medicine of today
  47. Post-traumatic biliobronchial fistula demonstrated on hepatobiliary scintigraphy with SPECT/CT
  48. Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer
  49. Biodistribution, toxicity and radiation dosimetry studies of the serotonin transporter radioligand 4-[ 18 F]-ADAM in rats and monkeys
  50. Development of 68 Ga-labelled DTPA galactosyl human serum albumin for liver function imaging
  51. Monitoring metastatic lesions in TENIS, initiating multi-targeted tyrosine kinase inhibitors and follow-up: should the newer FDG PET-CT quantitative indices be the defining objective parameter in clinical trials?
  52. Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer
  53. Validation of pixel-wise parametric mapping of myocardial blood flow with 13 NH 3 PET in patients with hypertrophic cardiomyopathy
  54. Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery
  55. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax
  56. Texture analysis of 18 F-FDG PET/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy
  57. Texture analysis of 18 F-FDG PET/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy
  58. PET imaging of HER1-expressing xenografts in mice with 86 Y-CHX-A″-DTPA-cetuximab
  59. Sensitivity of PET/MRI to detect recurrence of prostate cancer
  60. Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results
  61. Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer
  62. Metabolic-structural concordance in paraneoplastic limbic encephalitis
  63. Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer’s disease
  64. Abnormal response to inotropic stimulation in young asymptomatic type I diabetic patients demonstrated by serial gated myocardial perfusion SPECT imaging
  65. The “reset button” revisited: why high activity 131 I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patients
  66. Left ventricular dyssynchrony assessed by gated SPECT phase analysis is an independent predictor of death in patients with advanced coronary artery disease and reduced left ventricular function not undergoing cardiac resynchronization therapy
  67. FDG PET/CT methodology for evaluation of treatment response in lymphoma: from “graded visual analysis” and “semiquantitative SUVmax” to global disease burden assessment
  68. Procedure guidelines for PET/CT tumour imaging with 68 Ga-DOTA-conjugated peptides: 68 Ga-DOTA-TOC, 68 Ga-DOTA-NOC, 68 Ga-DOTA-TATE
  69. EANM 2010—Welcome to Vienna!
  70. 18 F-FDG PET/CT imaging versus dynamic contrast-enhanced CT for staging and prognosis of inflammatory breast cancer
  71. In vitro detection of mdr 1 mRNA in murine leukemia cells with 111 In-labeled oligonucleotide
  72. Therapeutic nuclear medicine expands to breast cancer
  73. Introduction to EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD)
  74. Radioiodinated SB 207710 as a radioligand in vivo: imaging of brain 5-HT 4 receptors with SPET
  75. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls
  76. Are Health Technology Assessments a reliable tool in the analysis of the clinical value of PET in oncology? Who audits the auditors?
  77. Defining optimal tracer activities in pediatric oncologic whole-body 18 F-FDG-PET/MRI
  78. The impact of reconstruction method on the quantification of DaTSCAN images
  79. Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma
  80. Role of pre-operative imaging using 99m Tc-MIBI and neck ultrasound in patients with secondary hyperparathyroidism who are candidates for subtotal parathyroidectomy
  81. Intracoronary brachytherapy for in-stent restenosis: will it remain a viable therapy?
  82. Radiation exposure to surgical staff during F-18-FDG-guided cancer surgery
  83. The role of 131 I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma
  84. Breast lymphatic drainage via the pulmonary lymphatic system
  85. Respiratory motion artefact in the liver dome on FDG PET/CT: comparison of attenuation correction with CT and a caesium external source
  86. Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype
  87. Feasibility of sodium/iodide symporter gene as a new imaging reporter gene: comparison with HSV1-tk
  88. Value of 11 C-choline PET and PET/CT in patients with suspected prostate cancer

Search Result: